[go: up one dir, main page]

MX2016009529A - Hibridosomas, composiciones que comprenden los mismos, procesos para su produccion y usos de los mismos. - Google Patents

Hibridosomas, composiciones que comprenden los mismos, procesos para su produccion y usos de los mismos.

Info

Publication number
MX2016009529A
MX2016009529A MX2016009529A MX2016009529A MX2016009529A MX 2016009529 A MX2016009529 A MX 2016009529A MX 2016009529 A MX2016009529 A MX 2016009529A MX 2016009529 A MX2016009529 A MX 2016009529A MX 2016009529 A MX2016009529 A MX 2016009529A
Authority
MX
Mexico
Prior art keywords
same
processes
compositions
hybridosomes
production
Prior art date
Application number
MX2016009529A
Other languages
English (en)
Other versions
MX384911B (es
Inventor
De Beer Joel
Original Assignee
Anjarium Biosciences Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anjarium Biosciences Ag filed Critical Anjarium Biosciences Ag
Publication of MX2016009529A publication Critical patent/MX2016009529A/es
Publication of MX384911B publication Critical patent/MX384911B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)

Abstract

La presente invención proporciona un vehículo biocompatible híbrido (hibridosoma) que comprende elementos estructurales y bioactivos que se originan de al menos un módulo de liberación biocompatible (MLB) y al menos un módulo de encapsulación de fármacos modificado por ingeniería (MEFI) que comprende al menos un resto fusogénico ajustable. La invención proporciona además composiciones farmacéuticas que comprenden dichos hibridosomas, procesos para su fabricación, así como usos farmacéuticos y métodos farmacéuticos basados en los mismos.
MX2016009529A 2014-01-21 2015-01-20 Hibridosomas, composiciones que comprenden los mismos, procesos para su producción y usos de los mismos. MX384911B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461929559P 2014-01-21 2014-01-21
PCT/IB2015/050436 WO2015110957A2 (en) 2014-01-21 2015-01-20 Hybridosomes, compositions comprising the same, processes for their production and uses thereof

Publications (2)

Publication Number Publication Date
MX2016009529A true MX2016009529A (es) 2016-10-17
MX384911B MX384911B (es) 2025-03-14

Family

ID=52434912

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016009529A MX384911B (es) 2014-01-21 2015-01-20 Hibridosomas, composiciones que comprenden los mismos, procesos para su producción y usos de los mismos.
MX2021000174A MX2021000174A (es) 2014-01-21 2016-07-21 Hibridosomas, composiciones que comprenden los mismos, procesos para su produccion y usos de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021000174A MX2021000174A (es) 2014-01-21 2016-07-21 Hibridosomas, composiciones que comprenden los mismos, procesos para su produccion y usos de los mismos.

Country Status (13)

Country Link
US (3) US10561610B2 (es)
EP (2) EP3096741B1 (es)
JP (3) JP6598786B2 (es)
KR (3) KR102541164B1 (es)
CN (2) CN112870163A (es)
AU (3) AU2015208837B2 (es)
CA (1) CA2936514C (es)
DK (1) DK3096741T3 (es)
EA (1) EA037503B1 (es)
ES (1) ES2821758T3 (es)
MX (2) MX384911B (es)
WO (1) WO2015110957A2 (es)
ZA (1) ZA201604831B (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013070324A1 (en) 2011-11-07 2013-05-16 University Of Louisville Research Foundation, Inc. Edible plant-derived microvesicle compositions for diagnosis and treatment of disease
WO2014210448A1 (en) 2013-06-27 2014-12-31 The Board Of Regents Of The University Of Texas System Compositions and methods relating to myomaker-induced muscle cell fusion
CA2936514C (en) 2014-01-21 2023-08-08 Joel DE BEER Hybridosomes, compositions comprising the same, processes for their production and uses thereof
US20170035700A1 (en) 2014-04-11 2017-02-09 University Of Louisville Research Foundation, Inc. Coated edible plant-derived microvesicle compositions and methods for using the same
WO2016123163A2 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
WO2017136430A1 (en) 2016-02-01 2017-08-10 The Board Of Trustees Of The Leland Stanford Junior University Exosome-total-isoloation-chip (exotic) device for isolation of exosome-based biomarkers
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
CN107362370B (zh) * 2016-05-13 2022-07-26 国家纳米科学中心 一种基于金纳米簇联合NGF siRNA治疗胰腺癌的方法
WO2017201340A2 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding relaxin
CN106280533B (zh) * 2016-08-17 2018-03-09 赣南师范大学 一种近红外荧光染料及其合成方法和用于寄生虫荧光标记
EP3292861A1 (en) * 2016-09-13 2018-03-14 Centre National De La Recherche Scientifique (Cnrs) An in vitro method for obtaining a biohybrid vector
BR112019022016A2 (pt) * 2017-04-19 2020-05-12 Apa- Advanced Technologies Ltd. Lipossomas fusogênicos, composições, kits e uso dos mesmos no tratamento do câncer
CN107084956B (zh) * 2017-05-05 2021-03-23 曲阜师范大学 一种基于醇溶剂诱导银纳米簇荧光增强的尿液中碘离子检测方法
BR112019023323A2 (pt) * 2017-05-08 2020-07-21 Flagship Pioneering Innovations V, Inc. composições para facilitar a fusão de membrana e usos das mesmas
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. RNA FORMULATIONS
KR20200044806A (ko) 2017-07-28 2020-04-29 내셔널 유니버시티 오브 싱가포르 변형된 유령 세포를 포함하는 생물분자 복합체
JP7275111B2 (ja) 2017-08-31 2023-05-17 モデルナティエックス インコーポレイテッド 脂質ナノ粒子の生成方法
US20200362038A1 (en) * 2017-09-11 2020-11-19 The Regents Of The University Of California Antibody-mediated delivery of cas9 to mammalian cells
WO2019066434A1 (ko) * 2017-09-30 2019-04-04 주식회사 엑소코바이오 사포게닌과 엑소좀을 유효성분으로 포함하는 조성물
KR102008665B1 (ko) * 2017-09-30 2019-08-08 주식회사 엑소코바이오 사포게닌과 엑소좀을 유효성분으로 포함하는 조성물
WO2019092550A1 (en) * 2017-11-13 2019-05-16 Politecnico Di Torino Biomimetic non-immunogenic nanoassembly for the antitumor therapy
US12036262B2 (en) 2017-11-22 2024-07-16 University Of Louisville Research Foundation, Inc. Edible plant-derived nanoparticles for regulation of gut microbiota
CN108287134B (zh) * 2017-12-28 2020-11-24 南京邮电大学 单颗粒生物探针及其等离子体生物存储器的构建方法
KR20200144093A (ko) * 2018-02-17 2020-12-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 막 단백질 전달을 위한 조성물 및 방법
US12241888B2 (en) 2018-03-14 2025-03-04 Children's Medical Center Corporation Platform for assessment of the transcytosis of extracellular vesicles across endothelial barriers and uses thereof
JP7551110B2 (ja) * 2018-04-06 2024-09-17 ノース カロライナ ステート ユニバーシティ 癌免疫療法のためのチェックポイント阻害剤の細胞集団を介した送達
EP3773520A4 (en) 2018-04-09 2021-12-22 Orgenesis Inc. BIOXOMES AND REDOXOMES PARTICLES, PROCESS AND COMPOSITION
WO2019210189A1 (en) * 2018-04-26 2019-10-31 University Of Louisville Research Foundation, Inc. Edible plant exosome-like nanovectors for vaccination
CA3003032A1 (en) * 2018-04-27 2019-10-27 Nanostics Inc. Methods of diagnosing disease using microflow cytometry
CN110437628B (zh) * 2018-05-04 2021-05-04 中国石油化工股份有限公司 一种改性剂母液和道路沥青及其合成方法
BR112020023015A2 (pt) * 2018-05-15 2021-02-17 Flagship Pioneering Innovations V, Inc. composições de fusossoma e usos das mesmas
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
CN112543629A (zh) * 2018-06-28 2021-03-23 阿斯利康(瑞典)有限公司 外泌体胞外囊泡及其使用方法
EP3820509A1 (en) 2018-07-09 2021-05-19 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
EA202190688A1 (ru) 2018-10-09 2021-06-07 Дзе Юниверсити Оф Бритиш Коламбиа Композиции и системы, содержащие трансфекционно-компетентные везикулы, не содержащие органических растворителей и детергентов, и связанные с ними способы
CA3117914A1 (en) * 2018-10-24 2020-04-30 Apa- Advanced Technologies Ltd. Fusogenic liposomes for selective imaging of tumor cells
US12496274B2 (en) 2018-11-14 2025-12-16 Flagship Pioneering Innovations V, Inc. Compositions and methods for compartment-specific cargo delivery
AU2019380517A1 (en) * 2018-11-14 2021-06-03 Flagship Pioneering Innovations V, Inc. Fusosome compositions for hematopoietic stem cell delivery
CN109620969B (zh) * 2019-01-30 2021-02-05 广东药科大学 一种针对耐药肿瘤细胞的靶向抗肿瘤药物体系及其构建方法
WO2021010586A1 (ko) * 2019-07-15 2021-01-21 (주)심플스틱 항노화를 위한 피부 리프팅용 화장료 조성물 및 이를 이용한 피부미용 방법
CN114945555A (zh) * 2019-08-12 2022-08-26 集成纳米治疗股份有限公司 用于荷电材料递送的脂质、其制剂及其制备方法
WO2021034582A1 (en) * 2019-08-16 2021-02-25 Children's Medical Center Corporation Large scale production of exosome mimetics and uses thereof
CN112415081A (zh) * 2019-08-23 2021-02-26 四川大学 一种基于稳定同位素检测的无标记CRISPR-Cas9分析方法
KR102297995B1 (ko) * 2019-10-24 2021-09-02 포항공과대학교 산학협력단 개방 동공을 갖는 산화철 나노큐브, 이의 제조방법 및 이의 용도
CN111007170B (zh) * 2019-12-13 2021-06-29 中国农业科学院农产品加工研究所 骨肽干预治疗骨质疏松中的生物标志物、筛选方法及用途
TW202139976A (zh) * 2020-01-31 2021-11-01 美商現代公司 製備脂質奈米顆粒之方法
EP3858332A1 (en) * 2020-01-31 2021-08-04 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bottom-up assembly of synthetic extracellular vesicles
EP4110296A1 (en) * 2020-02-25 2023-01-04 Translate Bio, Inc. Improved processes of preparing mrna-loaded lipid nanoparticles
CA3172121A1 (en) * 2020-03-20 2021-09-23 Gert Fricker Colloidal carrier systems for transfer of agents to a desired site of action
BR112023001648A2 (pt) 2020-07-27 2023-04-04 Anjarium Biosciences Ag Moléculas de dna de fita dupla, veículo de entrega e método para preparar uma molécula de dna com extremidade em grampo
CN112094809A (zh) * 2020-10-19 2020-12-18 军事科学院军事医学研究院环境医学与作业医学研究所 一种从血清或血浆中提取外泌体的方法
CA3216353A1 (en) 2021-04-08 2022-10-13 Sana Biotechnology, Inc. Cd8-specific antibody constructs and compositions thereof
JP2024514156A (ja) 2021-04-14 2024-03-28 アンジャリウム バイオサイエンシズ エージー Ｆｃ由来のポリペプチド
WO2022219075A2 (en) 2021-04-14 2022-10-20 Anjarium Biosciences Ag Peptides, nanovesicles, and uses thereof for drug delivery
JP2024522149A (ja) * 2021-06-04 2024-06-11 インスティテュート フォー ベーシック サイエンス ナノベシクルリアクター及びその製造方法
JP2024528697A (ja) 2021-07-20 2024-07-30 エイジーエス・セラピューティクス・ソシエテ・パール・アクシオン・サンプリフィエ 微細藻類由来の細胞外小胞、その調製および使用
JPWO2023027082A1 (es) * 2021-08-23 2023-03-02
WO2023144127A1 (en) 2022-01-31 2023-08-03 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
WO2023244084A1 (ko) * 2022-06-17 2023-12-21 주식회사 엠디뮨 양이온성 지질 및 핵산분자를 포함하는 세포유래 베지클 및 이의 제조방법
EP4608424A1 (en) 2022-10-24 2025-09-03 AGS Therapeutics SAS Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof
WO2024170778A1 (en) 2023-02-17 2024-08-22 Anjarium Biosciences Ag Methods of making dna molecules and compositions and uses thereof
US11944604B1 (en) 2023-03-10 2024-04-02 King Saud University Nanoformulation of spriooxindole and methods for treating hepatocellular carcinoma
WO2024249782A2 (en) * 2023-06-02 2024-12-05 The Methodist Hospital Biomimetic proteolipid nanovesicles for delivery of nucleic acids
WO2025008499A1 (en) 2023-07-06 2025-01-09 Anjarium Biosciences Ag Methods and compositions for purifying particles and macromolecules
KR20250018222A (ko) * 2023-07-26 2025-02-05 차의과학대학교 산학협력단 미토콘드리아가 캡슐화된 세포막 융합유도 리포좀을 포함하는 골관절염 치료를 위한 약학 조성물
WO2025100747A1 (ko) * 2023-11-09 2025-05-15 주식회사 엑토좀 줄기세포 유래 엑토-리포좀 융합 나노입자 및 그의 용도
WO2025137252A1 (en) * 2023-12-20 2025-06-26 Cz Biohub Sf, Llc High throughput method for screening lipid nanoparticle efficacy and cytotoxicity
WO2025176843A1 (en) 2024-02-21 2025-08-28 Ags Therapeutics Sas Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof
KR20250150723A (ko) * 2024-04-11 2025-10-21 주식회사 하이셀텍 하이브리드 엑소좀 및 이의 용도

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552155A (en) * 1992-12-04 1996-09-03 The Liposome Company, Inc. Fusogenic lipsomes and methods for making and using same
EP1519714B1 (en) * 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
AU2008207735B2 (en) * 2007-01-26 2013-10-03 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
EP2326331A4 (en) 2008-08-18 2013-05-15 Merck Sharp & Dohme NEW LIPID NANOPARTICLES AND NEW COMPONENTS FOR THE RELEASE OF NUCLEIC ACIDS
WO2010080724A1 (en) 2009-01-12 2010-07-15 Merck Sharp & Dohme Corp. Novel lipid nanoparticles and novel components for delivery of nucleic acids
US20130053426A1 (en) 2009-04-17 2013-02-28 Yiqi Seow Composition For Delivery Of Genetic Material
KR100950713B1 (ko) 2009-07-15 2010-03-31 (주)블루앤 음이온 발생기를 구비한 엘이디 램프
US9181295B2 (en) 2009-08-20 2015-11-10 Sirna Therapeutics, Inc. Cationic lipids with various head groups for oligonucleotide delivery
EP2485770A4 (en) 2009-10-08 2013-04-10 Merck Sharp & Dohme Novel cationic lipids with short lipid chains for oligonucleotide delivery
SG10201407996PA (en) 2009-12-23 2015-01-29 Novartis Ag Lipids, lipid compositions, and methods of using them
EP2526113B1 (en) 2010-01-22 2016-08-10 Sirna Therapeutics, Inc. Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry
US20120315324A1 (en) * 2010-02-05 2012-12-13 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
JP5149921B2 (ja) * 2010-02-19 2013-02-20 学校法人君が淵学園 癌細胞増殖抑制性ハイブリッド型リポソーム製剤
ES2694100T3 (es) * 2010-04-07 2018-12-18 California Institute Of Technology Vehículo para distribuir un compuesto en una membrana mucosa y composiciones, procedimientos y sistemas relacionados
JP2013531634A (ja) 2010-05-24 2013-08-08 メルク・シャープ・エンド・ドーム・コーポレイション オリゴヌクレオチド送達のための新規なアミノアルコールカチオン性脂質
WO2011150264A2 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Synthetic nanocarrier combination vaccines
DK2575767T3 (en) 2010-06-04 2017-03-13 Sirna Therapeutics Inc HOWEVER UNKNOWN LOW MOLECULAR CATIONIC LIPIDS TO PROCESS OIGONUCLEOTIDES
JP5635690B2 (ja) * 2010-07-01 2014-12-03 ポステック アカデミー‐インダストリー ファウンデーション 細菌由来マイクロベシクルを用いた癌治療及び癌診断方法
KR101130137B1 (ko) 2010-07-02 2012-03-28 연세대학교 산학협력단 발광다이오드 모듈
WO2012024629A1 (en) 2010-08-20 2012-02-23 Selecta Biosciences, Inc. Synthetic nanocarrier vaccines comprising proteins obtained or derived from human influenza a virus hemagglutinin
JP5961170B2 (ja) 2010-09-20 2016-08-02 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． オリゴヌクレオチドの送達のための新規な低分子量カチオン性脂質
JP2013545723A (ja) 2010-09-30 2013-12-26 メルク・シャープ・エンド・ドーム・コーポレイション オリゴヌクレオチドの送達のための低分子量カチオン性脂質
US9029590B2 (en) 2010-10-21 2015-05-12 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
US9067882B2 (en) 2010-11-05 2015-06-30 Sirna Therapeutics, Inc. Low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
WO2012099805A2 (en) 2011-01-19 2012-07-26 Ocean Nanotech, Llc Nanoparticle based immunological stimulation
WO2013048734A1 (en) 2011-09-28 2013-04-04 Tufts Medical Center, Inc. Treatment and prevention of cardiovascular disease with cell derived lipid vesicles, microvesicles and exosomes
WO2013086373A1 (en) * 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
JP2013128452A (ja) * 2011-12-21 2013-07-04 Toshiba Corp 定量分析装置、定量分析方法、脂質膜小胞、及び試薬
CA2891911C (en) 2012-12-07 2023-03-07 Alnylam Pharmaceuticals, Inc. Improved nucleic acid lipid particle formulations
BR112015018877A2 (pt) 2013-02-07 2017-08-22 Externautics Spa Método para preparar uma composição farmacêutica, e, composição farmacêutica imunogênica
CA2936514C (en) 2014-01-21 2023-08-08 Joel DE BEER Hybridosomes, compositions comprising the same, processes for their production and uses thereof
BR112023001648A2 (pt) 2020-07-27 2023-04-04 Anjarium Biosciences Ag Moléculas de dna de fita dupla, veículo de entrega e método para preparar uma molécula de dna com extremidade em grampo
JP2024514156A (ja) 2021-04-14 2024-03-28 アンジャリウム バイオサイエンシズ エージー Ｆｃ由来のポリペプチド
WO2022219075A2 (en) 2021-04-14 2022-10-20 Anjarium Biosciences Ag Peptides, nanovesicles, and uses thereof for drug delivery
KR20240012370A (ko) 2021-04-20 2024-01-29 안자리움 바이오사이언시스 아게 아밀로-알파-1, 6-글루코시다제, 4-알파-글루카노트랜스퍼라제를 인코딩하는 dna 분자의 조성물, 이를 제조하는 방법 및 이를 사용하는 방법
US20250381294A1 (en) 2022-01-14 2025-12-18 Anjarium Biosciences Ag Compositions of DNA Molecules Encoding Factor VIII, Methods of Making Thereof, and Methods of Use Thereof

Also Published As

Publication number Publication date
US10561610B2 (en) 2020-02-18
AU2015208837A1 (en) 2016-08-11
KR20160110410A (ko) 2016-09-21
EP3096741A2 (en) 2016-11-30
CN112870163A (zh) 2021-06-01
US20230181467A1 (en) 2023-06-15
EP3096741B1 (en) 2020-09-02
KR20220061286A (ko) 2022-05-12
MX384911B (es) 2025-03-14
JP2022101548A (ja) 2022-07-06
US20200222324A1 (en) 2020-07-16
JP2017502997A (ja) 2017-01-26
CA2936514A1 (en) 2015-07-30
DK3096741T3 (da) 2020-09-28
US20160354313A1 (en) 2016-12-08
WO2015110957A2 (en) 2015-07-30
JP6598786B2 (ja) 2019-10-30
AU2022218603A1 (en) 2022-09-15
MX2021000174A (es) 2021-03-25
EP3791863A1 (en) 2021-03-17
AU2020227129B2 (en) 2022-06-30
EP3791863B1 (en) 2025-09-10
EA037503B1 (ru) 2021-04-05
CN105934240B (zh) 2021-02-09
US11484500B2 (en) 2022-11-01
KR102396026B1 (ko) 2022-05-09
US11944706B2 (en) 2024-04-02
ZA201604831B (en) 2018-05-30
CA2936514C (en) 2023-08-08
KR102507475B1 (ko) 2023-03-07
AU2022218603B2 (en) 2024-10-03
CN105934240A (zh) 2016-09-07
KR20230039752A (ko) 2023-03-21
ES2821758T3 (es) 2021-04-27
KR102541164B1 (ko) 2023-06-08
AU2020227129A1 (en) 2020-10-01
EA201691448A1 (ru) 2016-12-30
WO2015110957A3 (en) 2015-12-03
AU2015208837B2 (en) 2020-06-18
JP2019218349A (ja) 2019-12-26
JP7046872B2 (ja) 2022-04-04

Similar Documents

Publication Publication Date Title
MX2016009529A (es) Hibridosomas, composiciones que comprenden los mismos, procesos para su produccion y usos de los mismos.
ECSP17081744A (es) Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2018002794A1 (es) Compuestos bicíclicos
CL2017003205A1 (es) Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen.
CL2018001509A1 (es) Sistema de conexión de viga a columna y soporte resistente al momento que incluye tal sistema.
CL2017001171A1 (es) Peptidos macrocíclicos útiles como inmunomoduladores
MX390064B (es) Formas cristalinas de mononucleotido de beta-nicotinamida.
CL2018003265A1 (es) Modulares del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
DOP2014000194A (es) COMPUESTOS DE OXAZOLIDIN- 2- ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks
MX2016010216A (es) Composiciones farmaceuticas solidas de antagonistas de los receptores de androgenos.
MX2018009938A (es) Profarmacos de hormona paratiroidea (pth).
MX388752B (es) Composiciones novedosas, usos y métodos para hacerlas.
CR20200082A (es) Virus chikungunya inmunogénico
MX2017002469A (es) Composiciones de matrices extracelulares.
CO2017002472A2 (es) Formulación de acetato de abiraterona
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
MX2022013454A (es) Moduladores de la actividad del complemento.
CL2014002661A1 (es) Compuestos derivados de tienopirimidina o sus sales, como inhibidores de la alk quinasa; su proceso de preparacion; composicion farmaceutica que los comprende, util para el tratamiento del cancer.
CL2019003213A1 (es) Compuestos plaguicidas bicíclicos.
CR20150248A (es) Derivados de oxazolidin-2-ona-pirimidina
GT201700058A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
MX2015001051A (es) Derivados de manosa, un proceso para su preparacion y sus usos como un farmaco.
BR112017028549A2 (pt) derivados de pirimidina como inibidores de btk e usos dos mesmos